Utilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patients

dc.contributor.authorGelow, Kayla
dc.contributor.authorChalasani, Sai
dc.contributor.authorGreen, Kelsey
dc.contributor.authorLammert, Craig
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2023-07-05T13:07:20Z
dc.date.available2023-07-05T13:07:20Z
dc.date.issued2022
dc.description.abstractBackground: Complementary and alternative medicine (CAM) use has become increasingly common. It is also prevalent in patients with chronic liver disease, but the scope, depth, and safety of use is not well known. Aims: This study aimed to evaluate the prevalence and patterns of CAM use in autoimmune hepatitis (AIH) patients. Methods: Electronic invitation to complete a 22 item CAM-specific questionnaire was posted weekly to well-established AIH Facebook communities (combined membership of 4700 individuals) during a 6-week study period. Age ≥ 18 years and AIH diagnosis made by a treating physician were the eligibility criteria. Results: The prevalence of ever CAM use among participants was 56.4%, and nearly 42% used CAM after AIH diagnosis. Among those reporting CAM use after diagnosis, 53.7% (51/95) indicated CAM was used to mitigate AIH-related phenomenon, most often targeting liver inflammation/fibrosis (67.7%), fatigue (51%), joint pain (47.1%), and sleep issues (45.1%). Most frequent physical CAM strategies were exercise (49.5%) and yoga (34%), whereas most frequent consumable CAM included healthier eating (45.3%), cannabidiol preparations (45.3%), and probiotics (44.3%). Seventy-five percent reported that CAM improved AIH symptoms and no severe adverse events were reported. Conclusions: CAM use in AIH patients is prevalent, yet providers have historically failed to document their patient's CAM strategies. Beyond inherent drug-induced liver injury risk, drug-drug interactions remain a concern and could alter baseline immunosuppression levels in AIH. Despite a majority found CAM approaches that improved targeted symptoms, all were unable to alter the course of chronically prescribed medications by physicians.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationGelow K, Chalasani S, Green K, Lammert C. Utilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patients. Dig Dis Sci. 2022;67(7):2891-2898. doi:10.1007/s10620-021-07112-0en_US
dc.identifier.urihttps://hdl.handle.net/1805/34096
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s10620-021-07112-0en_US
dc.relation.journalDigestive Diseases and Sciencesen_US
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourcePMCen_US
dc.subjectComplementary & alternative medicineen_US
dc.subjectSupplementen_US
dc.subjectAutoimmune hepatitisen_US
dc.titleUtilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patientsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
10620_2021_Article_7112.pdf
Size:
570.67 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: